Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB-101 vaccine in CMV-seronegative kidney transplant recipients with CMV-seropositive living donors
NL-OMON48943Phase 2Withdrawn
- Sponsor
- HOOKIPA Pharma
- Start
- Oct 2018
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of HB-101 in cytomegalovirus disease (CMV) (5 arms), sponsored by HOOKIPA Pharma. Primary endpoints: Incidence and severity of adverse events, serious adverse events, and laboratory changes, Incidence and severity of localized or generalized injection site reactions and 3 more. Planned start Oct 2018; status: withdrawn.
02
Drugs
HB-101
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on NL-OMON48943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48943.